Aphton to Present at Rodman & Renshaw 7th Annual Healthcare Conference
November 03 2005 - 8:00AM
Business Wire
Aphton Corporation (NASDAQ:APHT), a biotechnology company focused
on the development of immunotherapies for the treatment of cancer,
announced today that Patrick Mooney, M.D., Chairman and Chief
Executive Officer, will present an overview of the Company at the
upcoming Rodman & Renshaw Techvest 7th Annual Healthcare
Conference to be held at the Palace Hotel in New York City. Dr.
Mooney's presentation will be on Tuesday, November 8th at 8:40 a.m.
ET. A live audio webcast of the presentation can be accessed by
visiting the Rodman & Renshaw conference website at
http://wsw.com/webcast/rrshq7/apht/. A replay of the presentation
will begin 3 hours after the actual presentation and will be
available for 30 days. About Aphton Aphton Corporation,
headquartered in Philadelphia, Pennsylvania is a clinical stage
biopharmaceutical company focused on developing targeted
immunotherapies for cancer. Aphton's products seek to empower the
body's own immune system to fight disease. Through the acquisition
of Igeneon AG in March 2005, Aphton acquired late-stage products,
IGN101, a cancer vaccine designed to induce an immune response
against EpCAM positive tumor cells, and IGN311, a fully humanized
antibody against the Lewis Y antigen. Aphton has strategic
alliances with Xoma for treating gastrointestinal and other
gastrin-sensitive cancers using anti-gastrin monoclonal and other
antibodies; and Daiichi Pure Chemicals for the development,
manufacturing and commercialization of gastrin-related diagnostic
kits. Aphton's most advanced product, Insegia(TM), targets the
hormone gastrin 17 in an attempt to treat gastrointestinal cancers.
For more information about Aphton or its programs please visit
Aphton's website at www.aphton.com. Safe Harbor This information is
qualified in its entirety by cautionary statements and risk factor
disclosure contained in Aphton's Securities and Exchange Commission
filings, including Aphton's report on Form 10-K filed with the
Commission on March 16, 2005. Aphton wishes to caution readers that
certain risks and uncertainties may have affected and could in the
future affect the drug development process and Aphton's business
and could cause actual results to differ materially from Aphton's
beliefs and expectations. These risk factors include, but are not
limited to: (1) Aphton's ability to fund the further development of
its research and development programs; (2) Aphton's ability to
successfully identify and consummate opportunities to broaden and
progress its research and development pipeline; (3) scientific
developments regarding immunotherapies; (4) Aphton's ability to
successfully integrate Igeneon's operations and product portfolio
with Aphton's operations and product portfolio; and (5) the actual
design, results and timing of preclinical and clinical studies for
Aphton's products and product candidates.
Aphton (NASDAQ:APHT)
Historical Stock Chart
From May 2024 to Jun 2024
Aphton (NASDAQ:APHT)
Historical Stock Chart
From Jun 2023 to Jun 2024